Switch theme
Sign up to access all valuation multiples
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
2013
132
LTM Revenue $3.2M
LTM EBITDA n/a
-$16.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Co-Diagnostics has a last 12-month revenue of $3.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Co-Diagnostics achieved revenue of $3.9M and an EBITDA of -$38.7M.
Co-Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Co-Diagnostics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.8M | $3.9M | XXX | XXX | XXX |
| Gross Profit | $28.7M | $2.6M | XXX | XXX | XXX |
| Gross Margin | 422% | 67% | XXX | XXX | XXX |
| EBITDA | -$41.5M | -$38.7M | XXX | XXX | XXX |
| EBITDA Margin | -609% | -989% | XXX | XXX | XXX |
| Net Profit | -$14.2M | -$35.3M | XXX | XXX | XXX |
| Net Margin | -209% | -902% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Co-Diagnostics's stock price is $0.
Co-Diagnostics has current market cap of $11.6M, and EV of -$16.0M.
See Co-Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$16.0M | $11.6M | XXX | XXX | XXX | XXX | $-1.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Co-Diagnostics has market cap of $11.6M and EV of -$16.0M.
Co-Diagnostics's trades at -5.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Co-Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Co-Diagnostics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$16.0M | XXX | XXX | XXX |
| EV/Revenue | -4.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.4x | XXX | XXX | XXX |
| P/E | -0.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCo-Diagnostics's NTM/LTM revenue growth is -53%
Co-Diagnostics's revenue per employee for the last fiscal year averaged $30K, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Co-Diagnostics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Co-Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Co-Diagnostics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -43% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -989% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1042% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $30K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 115% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 413% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 536% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1098% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Co-Diagnostics acquired XXX companies to date.
Last acquisition by Co-Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Co-Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Co-Diagnostics founded? | Co-Diagnostics was founded in 2013. |
| Where is Co-Diagnostics headquartered? | Co-Diagnostics is headquartered in United States of America. |
| How many employees does Co-Diagnostics have? | As of today, Co-Diagnostics has 132 employees. |
| Who is the CEO of Co-Diagnostics? | Co-Diagnostics's CEO is Mr. Dwight H Egan. |
| Is Co-Diagnostics publicy listed? | Yes, Co-Diagnostics is a public company listed on NAS. |
| What is the stock symbol of Co-Diagnostics? | Co-Diagnostics trades under CODX ticker. |
| When did Co-Diagnostics go public? | Co-Diagnostics went public in 2017. |
| Who are competitors of Co-Diagnostics? | Similar companies to Co-Diagnostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Co-Diagnostics? | Co-Diagnostics's current market cap is $11.6M |
| What is the current revenue of Co-Diagnostics? | Co-Diagnostics's last 12-month revenue is $3.2M. |
| What is the current EV/Revenue multiple of Co-Diagnostics? | Current revenue multiple of Co-Diagnostics is -5.0x. |
| What is the current revenue growth of Co-Diagnostics? | Co-Diagnostics revenue growth between 2023 and 2024 was -43%. |
| Is Co-Diagnostics profitable? | Yes, Co-Diagnostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
